Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Ilonka, Zsolt"'
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background There are limited data in the literature on the indirect costs associated with skin and soft tissue infections (SSTIs) in the pediatric population. This study aimed to conduct a systematic review of the indirect costs associated w
Externí odkaz:
https://doaj.org/article/13dbb56c742b4462b1de18fb51844f1b
Autor:
Adelaide A. Hebert, MD, Theodore Rosen, MD, Núria Albareda López, BS, Ilonka Zsolt, MD, PhD, Xavier Masramon
Publikováno v:
International Journal of Women's Dermatology, Vol 6, Iss 2, Pp 109-115 (2020)
Background: Ozenoxacin is a topical antibiotic approved in the United States for treatment of impetigo in adults and children age ≥2 months. This analysis evaluated the efficacy and safety of ozenoxacin in specific pediatric age groups. Methods: Da
Externí odkaz:
https://doaj.org/article/ac0ce70512e54d93a9be7c44aefc7a84
Publikováno v:
International Journal of Women's Dermatology, Vol 6, Iss 2, Pp 109-115 (2020)
International Journal of Women's Dermatology
International Journal of Women's Dermatology
Background: Ozenoxacin is a topical antibiotic approved in the United States for treatment of impetigo in adults and children age ≥2 months. This analysis evaluated the efficacy and safety of ozenoxacin in specific pediatric age groups. Methods: Da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e9d86df643b6b39941e55bd8589bfc8
http://www.sciencedirect.com/science/article/pii/S2352647519301169
http://www.sciencedirect.com/science/article/pii/S2352647519301169
Autor:
Jordi Vila, Ilonka Zsolt, Domingo Gargallo-Viola, María García-Castillo, Ian Morrissey, Yuly López, Rafael Cantón
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Aim: To explore the antibacterial spectrum of ozenoxacin and compare its in vitro activity with that of other antibacterial agents. Materials & methods: In 2010, 10,054 isolates were collected from 128 centers worldwide. Minimum inhibitory concentrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73e9a0275ba8e68e99b4cba236090349
https://doi.org/10.2217/fmb-2019-0089
https://doi.org/10.2217/fmb-2019-0089
Autor:
González-Juanatey, José R., Ezquerra, Eduardo Alegría, Martínez, Vicente Bertoméu, Gutiérrez, Pedro Conthe, de Santiago Nocito, Ana, Fradera, Ilonka Zsolt
Publikováno v:
In Revista Española de Cardiología (English Edition) 2008 61(6):611-619
Autor:
Ian Morrissey, Jordi Vila, María García-Castillo, Domingo Gargallo-Viola, Ilonka Zsolt, Marta Tato, Yuly López, Rafael Cantón
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Aim: To compare the in vitro activity of the anti-impetigo agent, ozenoxacin, and other antimicrobial agents against Gram-positive clinical isolates from skin and soft tissue infections. Materials & methods: Isolates were collected in two studies: 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be8d281625d5163613e0da45cb399e11
https://doi.org/10.2217/fmb-2017-0289
https://doi.org/10.2217/fmb-2017-0289
Autor:
José M. Castellano, Alfredo Gracia, Vivencio Barrios, Ilonka Zsolt, Valentin Fuster, Lisette Kaskens, José Emilio Ruiz, Juan Cosin-Sales
Publikováno v:
Revista Española de Cardiología. 70:42-49
Resumen Introduccion y objetivos Estimar los beneficios en salud y el coste-efectividad de una intervencion con un policomprimido (acido acetilsalicilico 100 mg, atorvastatina 20 mg y ramipril 10 mg) para la prevencion secundaria de eventos cardiovas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b7e0c2383d90b06e55593a8d9bd11a3
https://doi.org/10.1016/j.recesp.2016.05.011
https://doi.org/10.1016/j.recesp.2016.05.011
Publikováno v:
International Journal of Antimicrobial Agents. 56:106082
Background To evaluate the activity of ozenoxacin (OZN) in Staphylococcus aureus strains with overexpression of mepA and norA genes, which encode efflux pumps. Methods S. aureus NCTC-8325-1, S. aureus NCTC 8225-2 (overexpressing mepA), S. aureus SA 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48305c50db493b6f16871a6602282b1a
https://doi.org/10.1016/j.ijantimicag.2020.106082
https://doi.org/10.1016/j.ijantimicag.2020.106082
Autor:
Adelaide A, Hebert, Nuria, Albareda, Theodore, Rosen, Antonio, Torrelo, Ramon, Grimalt, Noah, Rosenberg, Ilonka, Zsolt, Xavier, Masramon
Publikováno v:
Journal of drugs in dermatology : JDD. 17(10)
Ozenoxacin is a novel topical antibacterial agent with potent bactericidal activity against Gram-positive bacteria that has been developed as a 1% cream for treatment of impetigo. This article presents pooled results of pivotal clinical trials of oze
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a08cba2df987fcbfef25aa6163d682af
https://pubmed.ncbi.nlm.nih.gov/30365584
https://pubmed.ncbi.nlm.nih.gov/30365584
Autor:
Cristina Tarragó, Lluís Pérez Esquirol, Fabiana D'Aniello, Antònia Arañó, Ilonka Zsolt, Laurence Lachamp
Publikováno v:
Future microbiology. 13
Aim: To assess different concentrations and formulations of topical ozenoxacin using a mouse model of Staphylococcus aureus dermal infection for identification of the best formulation for treating patients with impetigo. Materials & methods: The effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbf6156646527915dff62e495969c120
https://pubmed.ncbi.nlm.nih.gov/29745240
https://pubmed.ncbi.nlm.nih.gov/29745240